{
    "clinical_study": {
        "@rank": "11445", 
        "arm_group": [
            {
                "arm_group_label": "Fasted", 
                "arm_group_type": "Experimental", 
                "description": "Dacomitinib administered under fasted conditions"
            }, 
            {
                "arm_group_label": "Fed", 
                "arm_group_type": "Experimental", 
                "description": "Dacomitinib administered under fed conditions"
            }, 
            {
                "arm_group_label": "Antacid", 
                "arm_group_type": "Experimental", 
                "description": "Dacomitinib administered under antacid treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of the potential effect that the administration of food or antacid medication may\n      have in the oral absorption of dacomitinib relative to the administration of dacomitinib in\n      absence of food or antacid medication"
        }, 
        "brief_title": "Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects including males between the ages of 18 and 55 years.  Females of non\n             childbearing potential .\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  An informed consent document signed and dated by the subject.\n\n        Exclusion Criteria:\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  A positive urine drug screen.\n\n          -  Treatment with an investigational drug within 30 days (or as determined by the local\n             requirement) or the appropriate time based on the elimination characteristics of the\n             study medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702506", 
            "org_study_id": "A7471015"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fasted", 
                "description": "Overnight fasted subjects will receive a single 45 mg dose of dacomitinib", 
                "intervention_name": "dacomitinib fasted", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fed", 
                "description": "Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal", 
                "intervention_name": "dacomitinib fed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Antacid", 
                "description": "Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole", 
                "intervention_name": "dacomitinib+antacid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antacids", 
                "Anti-Ulcer Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Dacomitinib", 
            "PF-00299804", 
            "fed", 
            "fasted", 
            "antacid", 
            "relative Bioavailability"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7471015&StudyName=Evaluation%20Of%20The%20Potential%20Effect%20That%20The%20Administration%20Of%20Food%20Or%20Antacid%20Medication%20May%20Have%20In%20The%20Oral%20Absorption%20Of%20Dacomitini"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bruxelles", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 1 Three Period Crossover Study To Evaluate The Effect Of Food And Antacids On The Pharmacokinetics, Safety & Tolerability Of PF-299,804 In Healthy Volunteers Who Have Received PF-299,804", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8). For dacomitinib and PF-05199265", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "For dacomitinib and PF-05199265", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702506"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).For dacomitinib and PF-05199265", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. For dacomitinib and PF-05199265", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "3 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. For dacomitinib", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "For dacomitinib and PF-05199265", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. For dacomitinib", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. For dacomitinib", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}